Search Results for "RNAi"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

ILLUMINATE Clinical Trial Program Overview

This infographic details the ILLUMINATE clinical trial program which investigates the treatment of Primary Hyperoxaluria Type 1 with lumasiran.

Zilebesiran in combination with a standard-of-care antihypertensive in patients with inadequately controlled hypertension: Primary results from the phase 2 KARDIA-2 study

Zilebesiran as Add-On Therapy in Patients with Hypertension Inadequately Controlled with a Standard Antihypertensive Medication: Efficacy and Safety Results from the KARDIA-2 Study

Renal Function and Isolated Kidney Transplant Outcomes in Primary Hyperoxaluria Type 1 Long-term Lumasiran Treatment

Subgroup Results from KARDIA-2: Impact of Demographic and Baseline Disease Characteristics on Zilebesiran Response in Patients with Hypertension Uncontrolled by a Standard Oral Antihypertensive

HELIOS-B 12-Month Results from the Open-Label Extension Period of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

Vutrisiran reduces all-cause mortality, cardiovascular mortality, and cardiovascular events in patients with transthyretin amyloid cardiomyopathy: Analysis from the HELIOS-B trial

Long-term clinical outcomes of patients with acute hepatic porphyria who were not attack-free after 6 months of givosiran treatment in a subgroup analysis of the phase 3 ENVISION study

Maintenance or Improvement of Functional Capacity, Health Status, and Quality of Life with Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy: Data from the HELIOS-B Study

Impact of Baseline Heart Failure Severity on Efficacy of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial: A Subgroup Analysis

Impact of vutrisiran on outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial

Zilebesiran in combination with a standard-of-care antihypertensive in patients with inadequately controlled hypertension: Primary results from the phase 2 KARDIA-2 study

History of Polyneuropathy and Musculoskeletal Manifestations in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy in APOLLO-B

Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension

RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial

ATTRv-PN Expert Opinion Slide Deck

Recommendations from a panel of experts for the diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States.

A Phase 2 Study Evaluating the Effects of Mivelsiran, an Investigational RNA Interference Therapeutic, on Hemorrhagic and Nonhemorrhagic Manifestations of Cerebral Amyloid Angiopathy

Impact of Zilebesiran, an Investigational RNA Interference Therapeutic Targeting Hepatic Angiotensinogen, on Renin–Angiotensin System Biomarkers in Patients with Mild-to-Moderate Hypertension

Small Interfering RNA Targeting Amyloid-Beta Precursor Protein Reduces Alzheimer’s Disease Pathology in 5xFAD Mice and Abrogates Behavior Changes in Early Intervention Paradigm

Summary of RNA Interference

An overview of RNAi discovery, how RNAi works, and features of RNAi therapeutics

The Science of RNA interference (RNAi)

This slide deck provides an overview of the science of RNA interference (RNAi), including mechanism of action and delivery platforms.

Givosiran: Mechanism of Action and Chemical Properties

Standard response letter on the mechanism of action and chemical properties of givosiran.

Vutrisiran: Mechanism of Action

Standard response letter on the mechanism of action of vutrisiran.

Patisiran: Mechanism of Action

Standard response letter on the mechanism of action of patisiran.

Zilebesiran: Mechanism of Action

Standard response letter on the mechanism of action of zilebesiran.

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.

Search Results for "RNAi"

ILLUMINATE Clinical Trial Program Overview This infographic details the ILLUMINATE clinical trial program which investigates the treatment of Primary Hyperoxaluria Type 1 with lumasiran.

ATTRv-PN Expert Opinion Slide Deck Recommendations from a panel of experts for the diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States.

Summary of RNA Interference An overview of RNAi discovery, how RNAi works, and features of RNAi therapeutics

The Science of RNA interference (RNAi) This slide deck provides an overview of the science of RNA interference (RNAi), including mechanism of action and delivery platforms.

Givosiran: Mechanism of Action and Chemical Properties Standard response letter on the mechanism of action and chemical properties of givosiran.

Vutrisiran: Mechanism of Action Standard response letter on the mechanism of action of vutrisiran.

Patisiran: Mechanism of Action Standard response letter on the mechanism of action of patisiran.

Zilebesiran: Mechanism of Action Standard response letter on the mechanism of action of zilebesiran.